Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II

Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II: Texture Analysis and Artificial Intelligence

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04394052

Acronym

TUMOSTEO II

Enrollment

740

Registered

2020-05-19

Start date

2020-06-01

Completion date

2030-06-01

Last updated

2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Neoplasm, Soft Tissue Neoplasm

Keywords

MRI, CT, Texture analysis, Ultra-high resolution, Tumors, Musculoskeletal

Brief summary

This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.

Detailed description

Comparison of values relating to the texture parameters of tumors evaluated by MRI and ultra-high resolution CT between benign and malignant lesions using histological analysis as the standard of reference. Comparison of the diagnostic performance of texture parameters derived from different MRI sequences and ultra-high resolution CT for musculoskeletal tumor characterization. Evaluate the impact of ultra-high resolution with respect to standard resolution on CT images Comparison of the diagnostic performance of the texture parameters for the tumor on the diagnostic performance of texture analysis derived parameters for the characterization of musculoskeletal tumors. Evaluate the effectiveness and accuracy of automatic artificial intelligence (AI) based tumor segmentation tools. Evaluate the use of trabecular analysis on ultra-high resolution CT images for the evaluation of tumor-bone interfaces.

Interventions

DIAGNOSTIC_TESTMR imaging

Medical imaging

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients suspected to have a bone or soft-tissue tumor referred for imaging for initial tumors characterization and staging.

Exclusion criteria

* Pregnancy * Breast feeding patients * Renal insufficiency * Contra indications to MRI or CT * Prior surgery or treatment to the evaluated lesion.

Design outcomes

Primary

Measure	Time frame	Description
Lesion benignancy or malignancy	Performed up to 6 months after CT and Magnetic Resonance (MR) imaging	Histologic determination of lesion aggressiveness (benign versus malignant) on core biopsy material

Secondary

Measure	Time frame	Description
Sarcoma FNCLCC (fédération Nationale des Centres de Lutte Contre le Cancer) grade	Performed up to 1 year after CT and MR imaging	Histologic grade of the sarcomas included in the study population with surgical resection material

Countries

France

Contacts

Primary ContactPedro Gondim Teixieira, PhD

p.teixeira@chru-nancy.fr+33 3 83 85 21 61

Backup ContactGabriela Hossu, PhD

g.hossu@chru-nancy.fr+33 3 83 15 50 96

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026